Menu

CMS

Medicare Part B plans to continue paying average sales price plus 6% for for 340B acquired drugs and biologicals in 2024, the U.S. Centers for Medicare & Medicaid Services said July 13.

Medicare Part B Keeping Default Pay Rate for 340B Drugs, Says OPPS Proposed Rule

July 18, 2023 Rich Daly, Editor in Chief 340B Report Views

Medicare Part B plans to continue paying the statutory default rate—generally average sales price plus 6%—for 340B acquired drugs and [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Rich Daly

U.S. Chamber of Commerce Asks Court to Pause Medicare Drug Price Negotiations

340B Is “Off the Rails,” Civil Rights Leader Chavis Says in Nationally Syndicated Op-Ed